drugset / Trial / NCT00643448

Explorative Study of AZD1305 in Atrial Fibrillation Patients

NCT00643448

Phase 2 Completed 65 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Explorative study in Atrial Fibrillation patients to assess Safety and Pharmacokinetics at initiation of treatment and at steady state

Timeline

Start
2008-03
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1305 Small molecule 125 mg

Indications